Adeno-associated virus (AAV)-based vectors are promising tools for gene therapeutic applications, in part because AAVs are nonpathogenic viruses, and vectors derived from them can drive long-term transgene expression without integration of the vector DNA into the host genome. AAVs are not strongly immunogenic, but they can, nonetheless, give rise to both a cellular and humoral immune response. As a result, a significant fraction of potential patients for AAV-based gene therapy harbors pre-existing antibodies against AAV. Because even very low levels of antibodies can prevent successful transduction, antecedent anti-AAV antibodies pose a serious obstacle to the universal application of AAV gene therapy. In this review, we discuss the current knowledge of the role of anti-AAV antibodies in AAV-based gene therapy with a particular emphasis on approaches to overcome the hurdle that they pose.
Get full access to this article
View all access options for this article.
References
1.
AsokanA., SchafferD.V., SamulskiR.J.2012. The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther., 20:699–708.
2.
AtchisonR.W.1970. The role of herpesviruses in adenovirus-associated virus replication in vitro. Virology, 42:155–62.
BartelM., SchafferD., BuningH. 2011. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol., 2:204.
5.
BeckmanR.A., MildvanA.S., LoebL.A.1985. On the fidelity of DNA replication: manganese mutagenesis in vitro. Biochemistry, 24:5810–7.
6.
BlacklowN.R., HogganM.D., KapikianA.Z.et al.1968. Epidemiology of adenovirus-associated virus infection in a nursery population. Am. J. Epidemiol., 88:368–78.
7.
BoutinS., MonteilhetV., VeronP.et al.2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther., 21:704–12.
8.
CalcedoR., VandenbergheL.H., GaoG.et al.2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis., 199:381–90.
9.
CalcedoR., MorizonoH., WangL.et al.2011. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol., 18:1586–8.
10.
CarlisleR.C., BenjaminR., BriggsS.S.et al.2008. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J. Gene Med., 10:400–11.
11.
CassinottiP., WeitzM., TratschinJ.D.1988. Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1. Virology, 167:176–84.
12.
ChaputJ.C., WoodburyN.W., StearnsL.A., WilliamsB.A.2008. Creating protein biocatalysts as tools for future industrial applications. Expert Opin. Biol. Ther., 8:1087–98.
13.
ChirmuleN., PropertK., MagosinS.et al.1999. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther., 6:1574–83.
ClineJ., BramanJ.C., HogrefeH.H.1996. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res., 24:3546–51.
16.
CroyleM.A., ChirmuleN., ZhangY., WilsonJ.M.2001. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol., 75:4792–801.
17.
CroyleM.A., ChirmuleN., ZhangY., WilsonJ.M.2002. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther., 13:1887–900.
18.
DavidoffA.M., GrayJ.T., NgC.Y.et al.2005. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol. Ther., 11:875–88.
19.
DubeD.K., LoebL.A.1975. Manganese as a mutagenic agent during in vitro DNA synthesis. Biochem. Biophys. Res. Commun., 67:1041–6.
20.
EckertK.A., KunkelT.A.1991. DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl., 1:17–24.
21.
ErlesK., SebökovàP., SchlehoferJ.R.1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)J. Med. Virol., 59:406–11.
GaoG., VandenbergheL.H., AlviraM.R.et al.2004. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol., 78:6381–8.
24.
GaoG.P., AlviraM.R., WangL.et al.2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U S A, 99:11854–9.
25.
GruberK.2012. Europe gives gene therapy the green light. Lancet, 380:e10.
26.
GurdaB.L., RauppC., Popa-WagnerR.et al.2012. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol., 86:7739–51.
27.
HalbertC.L., RutledgeE.A., AllenJ.M.et al.2000. Repeat transduction in the mouse lung by Using adeno-associated virus vectors with different serotypes. J. Virol., 74:1524–32.
28.
HarrisJ.M., ChessR.B.2003. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2:214–21.
29.
HermonatP.L., MuzyczkaN.1984. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA, 81:6466–70.
30.
HurlbutG.D., ZieglerR.J., NietupskiJ.B.et al.2010. Pre-existing immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther., 18:1983–94.
31.
KerrJ.R.2006. Parvoviruses. Hodder Arnold; distributed in the United States by Oxford University Press: London/New York.
32.
KotinR.M., LindenR.M., BernsK.I.1992. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J., 11:5071–8.
33.
KotinR.M., SiniscalcoM., SamulskiR.J.et al.1990. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A., 87:2211–5.
34.
LabrouN.E.2010. Random mutagenesis methods for in vitro directed enzyme evolution. Curr. Protein Pept. Sci., 11:91–100.
35.
LeH.T., YuQ.C., WilsonJ.M., CroyleM.A.2005. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J. Control Release, 108:161–77.
LindenR.M., WardP., GiraudC.et al.1996. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A., 93:11288–94.
38.
LochrieM.A., TatsunoG.P., ChristieB.et al.2006. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol., 80:821–34.
39.
LusbyE., FifeK.H., BernsK.I. 1980. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol., 34:402–9.
40.
LusbyE., BohenzkyR., BernsK.I.1981. Inverted terminal repetition in adeno-associated virus DNA: independence of the orientation at either end of the genome. J. Virol., 37:1083–6.
41.
MaerschS., HuberA., BüningH.et al.2010. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology, 397:167–75.
MendelsonE., TrempeJ.P., CarterB.J.1986. Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J. Virol., 60:823–32.
44.
MingozziF., HasbrouckN.C., Basner-TschakarjanE.et al.2007. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 110:2334–41.
45.
MingozziF., MeulenbergJ.J., HuiD.J.et al.2009. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 114:2077–86.
46.
MingozziF., ChenY., EdmonsonS.C.et al.2012a. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther.[Epub ahead of print]10.1038/gt.2012.55
47.
MingozziF., ChenY., MurphyS.L.et al.2012b. Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B. Mol. Ther., 20:1410–6.
48.
MonteilhetV., SahebS., BoutinS.et al.2011. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther., 19:2084–91.
49.
MoskalenkoM., ChenL., Van RoeyM.et al.2000. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol., 74:1761–6.
50.
MurphyS.L., LiH., MingozziF.et al.2009. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol., 81:65–74.
51.
NathwaniA.C., TuddenhamE.G., RangarajanS.et al.2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365:2357–65.
52.
NonnenmacherM., WeberT.2012. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther., 19:649–58.
53.
OgstonP., RajK., BeardP.2000. Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein. J. Virol., 74:3494–504.
54.
O'RiordanC.R., LachapelleA., DelgadoC.et al.1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther., 10:1349–58.
55.
PeraboL., EndellJ., KingS.et al.2006. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med., 8:155–62.
56.
RaperS.E., WilsonJ.M., NunesF.A.2013. Flushing out antibodies to make aav gene therapy available to more patients. Mol Ther., 21:269–271.
57.
RaptiK., HajjarR.J., WeberT.2012. Novel approaches to deliver molecular therapeutics in cardiac disease using adeno-associated virus vectors. Translational Cardiology, 391–458.
58.
SamulskiR.J., BernsK.I., TanM., MuzyczkaN.1982. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl. Acad. Sci. U.S.A., 79:2077–81.
59.
SamulskiR.J., ZhuX., XiaoX.et al.1991. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J., 10:3941–50.
60.
SenapathyP., TratschinJ.D., CarterB.J.1984. Replication of adeno-associated virus DNA. Complementation of naturally occurring rep- mutants by a wild-type genome or an ori- mutant and correction of terminal palindrome deletions. J. Mol. Biol., 179:1–20.
61.
SonntagF., SchmidtK., KleinschmidtJ.A.2010. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA, 107:10220–5.
62.
SonntagF., KotherK., SchmidtK.et al.2011. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol., 85:12686–97.
63.
StemmerW.P.1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature, 370:389–91.
64.
TindallK.R., KunkelT.A.1988. Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. Biochemistry, 27:6008–13.
65.
TratschinJ.D., WestM.H., SandbankT., CarterB.J.1984. A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol. Cell Biol., 4:2072–81.
66.
VeronP., LeborgneC., MonteilhetV.et al.2012. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol., 188:6418–24.
67.
WangL., CalcedoR., BellP.et al.2011. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum. Gene Ther., 22:1389–401.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
